University of Maryland, Greenebaum Cancer Center, Baltimore, MD, USA.
Cancer Biol Ther. 2010 Nov 1;10(9):830-8. doi: 10.4161/cbt.10.9.13622.
Multiple Myeloma is a molecularly heterogeneous disease with a high degree of genomic instability in which specific genetic changes can be linked to clinical presentation and prognosis. Despite recent improvements in event-free survival and overall survival with the use of high dose chemotherapy and stem cell support as well as the development of novel agents such as thalidomide, lenalidomide and Bortezomib, MM remains an incurable disease. The development of effective targeted therapies requires a detailed knowledge of various genetic and signaling pathways governing MM genesis. This review will focus on the current understanding of the molecular pathogenesis of MM and the intracellular signaling pathways and their regulations, with emphasis on the rationale for identifying therapeutic targets that can be applied in the clinic.
多发性骨髓瘤是一种分子异质性疾病，具有高度的基因组不稳定性，其中特定的遗传变化可以与临床表现和预后相关。尽管最近使用高剂量化疗和干细胞支持以及新型药物如沙利度胺、来那度胺和硼替佐米的应用，使无事件生存和总生存得到了改善，但 MM 仍然是一种不可治愈的疾病。有效的靶向治疗的发展需要详细了解控制 MM 发生的各种遗传和信号通路。这篇综述将重点介绍 MM 的分子发病机制以及细胞内信号通路及其调控的最新认识，强调确定可应用于临床的治疗靶点的合理性。
